Epidemiology and Trends in Hepatic Encephalopathy (HE) in the United States

Dr. Derek van Amerongen introduces a panel discussing hepatic encephalopathy (HE), noting that 30-40% of cirrhotic patients develop overt HE.

Now Viewing

EP: 1.Epidemiology and Trends in Hepatic Encephalopathy (HE) in the United States

EP: 2.Clinical Features and Risk Factors of Hepatic Encephalopathy and Their Impact on Patient Care

EP: 3.Understanding the Differential Diagnosis and Distinctions Between Overt and Covert Hepatic Encephalopathy

EP: 4.Navigating the Clinical and Economic Landscape of Hepatic Encephalopathy (HE)

EP: 5.Optimal Strategies for Managing the Burdens Associated with Hepatic Encephalopathy (HE)

EP: 6.Optimizing Therapy Goals and Managing Overt Hepatic Encephalopathy (HE)

EP: 7.Guidelines in Action and Navigating Overt Hepatic Encephalopathy (HE) Management

EP: 8.Strategies for Addressing Precipitating Factors and Comorbidities in Hepatic Encephalopathy (HE)

EP: 9.Optimizing Continuity of Care to Enhance Patient Outcomes and Reduce Hospitalizations in Hepatic Encephalopathy (HE)

EP: 10.Coordinated Care Strategies and Enhancing Patient Outcomes in Hepatic Encephalopathy (HE)

EP: 11.Navigating Insurance Challenges and Transitions of Care in Hepatic Encephalopathy (HE)

EP: 12.Diagnosis of hepatic encephalopathy (HE) with a Case Study

EP: 13.Collaborating with Payers to Improve Outcomes in HE

EP: 14.Final Thoughts on Advancing Hepatic Encephalopathy (HE) Management

---

This series was supported by Salix Pharmaceuticals.

Related Videos